



*This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

# Revision of Precautions

## Memantine hydrochloride

August 6, 2015

### Non-proprietary name

Memantine hydrochloride

### Safety measure

Precautions should be revised in the package insert.

In the Clinically significant adverse reactions subsection of the Adverse reactions section, the following text should be added (underlined parts are revised):

#### Rhabdomyolysis:

Rhabdomyolysis may occur. Patients should be carefully monitored. If symptoms including myalgia, feelings of weakness, increased creatine kinase (creatine phosphokinase), or increased myoglobin blood and urine are observed, administration of this drug should be discontinued and appropriate measures should be adopted.

In addition, caution should be exercised for development of acute kidney injury due to rhabdomyolysis.